November 16, 2018

S'UIMIN Inc.

SPARX Group Co., Ltd.

S'UIMIN Received ¥700 Million in Capital from Mirai Creation Fund

—First Investment from Mirai Creation Fund II—

Promoting Sleep Disorder Diagnostic Support Services for Medical Institutions and Healthcare Management Business

S'UIMIN Inc. (HQ: Tsukuba-shi, Ibaraki, Co-delegate CEO Masashi Yanagisawa and Co-delegate COO Masa Fujiwara, "S'UIMIN"), developer of sleep study services that leverage electroencephalography (brain wave) devices and AI technology, today announced that it has raised ¥700 million in capital from Mirai Creation Fund I (one) and Mirai Creation Fund II (two) operated by SPARX Group Co., Ltd. (HQ: Minato-ku, Tokyo, CEO Shuhei Abe, "SPARX"). In July 2018, SPARX announced that SPARX established the "Mirai Creation Fund II". The investment in S'UIMIN is the first case for SPARX to make use of Mirai Creation Fund II.

S'UIMIN began as a spin-out from the University of Tsukuba on October 17, 2017, and it was founded to commercialize the project sponsored by the Tsukuba Global Innovation Promotion Agency and Ibaraki Prefecture. The project was initially funded by the Program for Building Regional Innovation Ecosystems by the Ministry of Education, Culture, Sports, Science and Technology of Japan. With its vision, "To be a hope for all individuals unsatisfied with sleep," S'UIMIN develops electroencephalography devices that are comfortable to wear and that produce information equivalent to those from all-night polysomnography (PSG). This will be combined with AI-driven automatic sleep staging and other technologies. By 2020, S'UIMIN plans to acquire certification as medical devices for its products and to start offering sleep disorder diagnostic support services for medical institutions. At the same time, the firm will expand its services to corporations that are involved in healthcare management and, eventually, to the general public. By effectively preventing and accurately diagnosing sleep disorders, the firm aims to create a society in which every individual can live their lives happily without worrying about sleep.

Operating as a Technology Licensing Organization (TLO), the firm is also responsible for licensing technology developed through the research efforts of International Institute for Integrated Sleep Medicine (IIIS), University of Tsukuba, to the industrial sector. By building an ecosystem that promotes this industrial-academic collaboration through which the profits earned from the TLO business are returned to IIIS, S'UIMIN is able to accelerate the pace at which future innovation for sleep medicine.

■ Overview of the International Institute for Integrated Sleep Medicine (IIIS), University of Tsukuba

Aiming to clarify the mechanisms that regulate sleep and wakefulness, IIIS is a world-class sleep research institute that focuses on basic and translational science. It established the study of sleep medicine, which combines the three research fields of basic biology, pharmaceutical science, and experimental medicine. Its research activities are focused on these three fields. Masashi Yanagisawa, the international sleep researcher who discovered orexin—the brain substance that governs sleep and wake—and S'UIMIN's CEO, serves as the head of IIIS. In 2016, he discovered the genes that determine the amount of sleep, and in 2018, he published a study elucidating the biochemical mechanism underlying sleepiness. Both of these studies have been published in the scientific journal *Nature*, demonstrating the importance of Dr. Yanagisawa's research.

- Overview of Mirai Creation Fund I (one) and Mirai Creation Fund II (two)
  Mirai Creation Fund I (one) targets investment in enterprises and projects that possess innovative technologies in the core three areas of Intelligent Technology (e.g. artificial intelligence), robotics, and technologies for a hydrogen-powered society. It began its operations in November 2015 with SPARX as an operator, with investment of 13.5 billion yen by Toyota Motor Corporation, Sumitomo Mitsui Banking Corporation and SPARX. At the end of October 2018, 20 companies have invested in the Fund. The Fund has been investing in about 50 companies, in US, UK, Israel, Singapore and Japan. (https://mirai.sparx.co.jp/en/). On 31st July 2018, SPARX announces to launch Mirai Creation Fund II (two). In addition to the three categories of that Fund I focused on, the Mirai Creation Fund II mandate also includes electrification and new materials. The investment in S'UIMIN is the first case for SPARX to make use of Mirai Creation Fund II. Combining Mirai Creation Fund I and Fund II, AUM reaches 53 billion yen, at the end of October, 2018.

- Contact Information

  - S'UIMIN Inc.
    Tetsuroh Hiei
    Email: info@suimin.co.jp

  - SPARX Group Co., Ltd.
    Public Relations
    Telephone: +81-3-6711-9100
    Email: pr_media@sparxgroup.com